Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by wildbird1on Sep 15, 2019 12:11pm
216 Views
Post# 30128328

RE:RE:Any Oncore Pharma progress news will be posted on their site

RE:RE:Any Oncore Pharma progress news will be posted on their siteFor those that do not fully understand how a big Insurance Network or a large HealthCare System could save $100 million a year.
Let's take Chemotherapy as an exemple;
https://costaide.com/chemotherapy-cost/
Chemotherapy can cost $10,000USD early stage, up to $200,000USD late stage cancer.

If a big Insurance Network or a large HealthCare system, can stop just 10 patients from reaching late stage cancer ($200,000USD), they will save $2 millionUSD, 100 patients =$20 millionUSD saving, 1000 patients = very very big saving...

We must also remember that SZLS is targetting the Non-Compliants patients. 
EX; The 50% of patients that refuse to pay $675USD to poop in a box or to pass a Colonoscopy. 
Check "Results" in this link...
https://ncbi.nlm.nih.gov/pmc/articles/PMC1490266/
50% of patients refuse to pass a Colonoscopy, that is a huge number of Non-Compliants patients just for Colorectal cancer.

Non-Compliant patients is a very large market and SZLS seem to be for now the only company interested to undertake it.
Non-compliant patients because they refuse screening are more likely to be diagnosed with a late stage cancer($200,000USD).

That could explain why a Large HealthCare System has initiated a contract with SZLS.


wildbird1 wrote: Thank's Nailbiter1...

https://oncorepharma.com/

In the Clinical Utility (blue box last phrase) (QUOTE)'' ColonSentry can reduce HealthCare cost by more than 20% through early intervention" (End Of Quote).

A 20% saving for a large HealthCare System could mean hundreds of million a year. That alone could explain why a large HealthCare system has initiated(set in motion) a contract with SZLS.

As we have said many time before, saving money is the best sale pitch of all. But 20% saving is not just big money, it is very very big money.

No wonder the OncorePharma and SZLS peoples are so confident.


Nailbiter1 wrote:
https://oncorepharma.com/news/

In Canada, private clinics and Insurance companies are their top priority.
 




Bullboard Posts